PD-L1 (6C8) Monoclonal Antibody

$Lane 1: full-length PD-L1 transfected 293T; Lane 2: untransfected 293T, probed with PD-L1 (6C8) Monoclonal Antibody, Unconjugated (bsm-58003R) at 1:1000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.$

Lane 1: full-length PD-L1 transfected 293T; Lane 2: untransfected 293T, probed with PD-L1 (6C8) Monoclonal Antibody, Unconjugated (bsm-58003R) at 1:1000 dilution and 4\u02daC overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37\u02daC.

Flow cytometric analysis of 293F cells expressing PD-L1 probed with PD-L1 (6C8) Monoclonal Antibody, unconjugated (bsm-58003R) at 1:100 dilution (red), compared control IgG staining (blue).

Applications

Reactivity

Human

Overview
Catalog #	bsm-58003R
Product Name	PD-L1 (6C8) Monoclonal Antibody
Applications	WB FCM
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant human PD-L1 extracellular domain
Clonality	Monoclonal
Clone #	6C8
Isotype	IgG
Concentration	Not Determined
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	29126
Swiss Prot	Q9NZQ7
Synonyms	Programmed cell death 1 ligand 1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1; Programmed death ligand 1
Background	Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
Application Dilution
WB	1:300-5000
FCM	1:20-100